The process of neoangiogenesis is essential for solid tumor growth and tumor survival. Vascular endothelial growth factor (VEGF) is one of the most potent, highly specific angiogenic factors. 1, 2 It represents a heparin-binding, dimeric glycoprotein with a selective, receptor-transmitted mitogenic effect on vascular endothelial cells in vitro and a direct angiogenic effect in vivo. 3 VEGF acts via binding to at least 2 specific tyrosine kinase receptors, c-fms-like tyrosine kinase (Flt-1) and fetal liver kinase 1 (Flk-1), known to be expressed primarily by endothelial cells. 4, 5 Although several studies investigated VEGF expression in prostatic tissue, 6, 7 there is little information about the distribution of VEGF receptors in human prostatic tissue. However, this is of great importance to better assess the role of VEGF in prostate cancer growth. Reports on VEGF receptor expression in inflammatory cells indicate that the receptor-transmitted mitogenic effect of VEGF is not endothelial cell-specific. 8 Interestingly, animal studies could also show VEGF receptor expression by prostate cancer cells following hormonal deprivation therapy, 9 implicating a proliferative inductive function of VEGF not only on vascular endothelial cells, but also directly on prostate cancer cells. The aim of the present study was to examine the expression and labeling pattern of VEGF and its receptor Flk-1 in benign, premalignant, and malignant prostate tissue.
Materials and Methods
We studied radical prostatectomy specimens from 21 patients without any cancer-specific pretreatment. Pathologic tumor stage included stage T2 in 8 cases, stage T3 in 10, and stage T4 in 3 cases. Lymph nodes in all patients were free of tumor. © American Society of Clinical Pathologists
Immunohistochemical Analysis
The tissue was fixed in 4% buffered formalin and paraffin embedded. Serial 4-µm sections were cut for H&E histologic examination and immunohistochemical analysis. For each case, a block containing part of the main bulk of tumor was chosen as representative based on H&E staining, and consecutive sections of this block were submitted for immunohistochemical analysis.
Immunohistochemical staining for VEGF expression was carried out with a polyclonal rabbit antibody against human VEGF (Santa Cruz Biotechnology, Santa Cruz, CA), which reacts with the 165, 189, and 121 amino acid splice variants of VEGF. Staining for the VEGF receptor Flk-1 was carried out with a monoclonal mouse antibody against a recombinant protein corresponding to amino acids 1158-1345 mapping at the carboxy terminus of Flk-1 (Santa Cruz Biotechnology).
The sections were deparaffinized with xylene and rehydrated with graded concentrations of ethanol. Endogenous peroxidase was blocked by immersion in methanol with 0.3% hydrogen peroxide for 30 minutes at room temperature. VEGF required Proteinase K predigestion in a working dilution of 0.4 mg/mL for 10 minutes at room temperature. For optimal retrieval of the Flk-1 receptor, sections were boiled in citrate buffer in a microwave oven (3 times at 600 W for 5 minutes). Preceding incubation with the VEGF antibody, nonspecific binding was blocked by incubation with 5% skim milk for 30 minutes at room temperature. Preceding FLK-1 staining, unspecific binding was blocked with 5% normal rabbit serum in phosphate-buffered saline for 60 minutes at room temperature. Sections were incubated with the primary antibodies at 4°C overnight, using a working dilution of 1:400 with 5% skim milk in phosphate-buffered saline for VEGF and 1:200 for Flk-1. All immunohistochemical reactions were developed with the avidin-biotin peroxidase method using diaminobenzidine as the chromogen.
Renal tissue for VEGF and colon cancer tissue for Flk-1 served as positive controls. For all stainings, the primary antibody was omitted for negative controls.
Expression of VEGF and Flk-1 in secretory glandular cells was classified as follows: positive staining in fewer than 5% of cells, (+); 5% to 25%, +; >25% to <50%, ++; 50% to 75%, +++; and more than 75%, ++++. The intensity of immunoreactivity was subjectively graded as follows: no immunoreactivity, -; weak, +; moderate, ++; and strong, +++. In the same way, basal cell immunoreactivity in benign glands and high-grade prostatic intraepithelial neoplasia (HGPIN) was recorded.
Statistical Analysis
For statistical analysis, the Fisher exact test (2-sided) was used.
Results
Secretory and basal cells positive for VEGF showed diffuse cytoplasmic staining. Nuclei were negative. Anti-Flk-1 immunoreactive cells showed cytoplasmic staining, cell membrane-bound staining, or both. Nuclei were negative. The staining results of both markers in benign glands, HGPIN, and carcinoma are shown in detail in ❚Table 1❚, ❚Table 2❚, and ❚Table 3❚.
Benign glands were seen in 19 specimens. In all of them, fewer than 5% of the secretory glandular cells were positive for VEGF ❚Figure 1❚. In 15 cases, basal cells of benign glands showed very weak anti-VEGF immunoreactivity. In 11 of these cases, more than 50% and in 4 cases, fewer than 50% of the cells were positive. In another 4 cases, no basal cell staining was seen. Staining for Flk-1 was confined almost exclusively to the basal cells ❚Image 1❚. The basal cell layer was sharply and strongly labeled in all cases. In 16 of 19 cases (84%), fewer than 5% of the secretory cells in benign glands stained positive ❚Figure 2❚. In 11 of them (58%), secretory cells stained completely negative. In the remaining 8 cases, fewer than 25% of the cells stained positive. Staining intensity was weak in 3 cases and strong in 5 cases.
HGPIN was seen in 17 cases. Compared with benign glands, the percentage of VEGF-positive secretory cells in HGPIN was significantly higher (P < .0001). In all cases, VEGF immunoreactivity was seen in more than 75% of the cells ( Figure 1 ). In 11 cases (65%), staining intensity was moderate, and in 6 cases (35%), only weak immunoreactivity was seen. Assessment of basal cells status was possible in 13 cases. In 4, the percentage of immunoreactive basal cells was scored as (+). Two cases were scored as +++ and 7 cases as ++++. Staining intensity was scored as weak in 5 and moderate in 8 cases. Compared with benign glands, the percentage of Flk-1-positive secretory cells was significantly higher in HGPIN (P < .0001). Flk-1 staining was positive in all secretory cells of HGPIN (Image 1). Staining intensity was moderate in 3 and strong in 14 cases. Assessment of the basal cell layer in HGPIN was limited by its fragmentation in most of the cases. Nevertheless, in 15 of 17 cases, basal cells could be recognized. All stained positive for Flk-1. Staining intensity was scored as strong in 13 cases and moderate and weak in 1 case each.
The percentage of positive stained carcinoma cells was significantly higher than the percentage seen in secretory cells in benign glands (P < .0001) and almost corresponded to the results found in HGPIN. The majority of tumor cells showed VEGF and Flk-1 immunoreactivity (Figures 1 and  2 GS, Gleason score. * The percentage of positive cells was scored as follows: (+), <5%; +, 5%-25%; ++, >25%-<50%; +++, 50%-75%; ++++, >75%. The staining intensity was scored as follows: -, no immunoreactivity; +, weak; ++, moderate; +++, strong. stained weakly, whereas the Gleason grade 3 component showed more intense staining. In another carcinoma specimen with a Gleason score of 6, the tumor edge showed increased nuclear atypia, which was accompanied by intense VEGF and Flk-1 staining, compared with the light staining of the central part of the tumor ❚Image 5❚.
Discussion
The importance of tumor neoangiogenesis for tumor growth and progression has been shown for several urologic tumor types (for review see Jones and ❚Image 2❚ Gleason score 7 carcinoma. Moderate anti-vascular endothelial growth factor staining (avidin-biotin peroxidase technique, original magnification ×400).
❚Image 3❚ Gleason score 7 carcinoma. Strong anti-fetal liver kinase 1 staining (avidin-biotin peroxidase technique, original magnification ×400).
❚Image 4❚ Gleason score 4 carcinoma negative for vascular endothelial growth factor (avidin-biotin peroxidase technique, original magnification ×400). © American Society of Clinical Pathologists (neoangiogenesis) by activation of specific receptors that are expressed by endothelial cells. However, there is increasing evidence that VEGF receptors also are expressed by cells other than endothelial cells. 8 Knowledge of VEGF receptor expression in prostate cancer is limited.
Our study showed that in benign prostatic glands, VEGF and Flk-1 expression is confined mainly to the basal cell layer, which represents the proliferative cell compartment 11 of benign glandular epithelium. Preneoplastic and neoplastic transformation is associated with loss of an orderly epithelial stratification (basal cell layer, secretory cells). This is reflected in the VEGF and Flk-1 labeling patterns. In HGPIN, labeling is no longer confined to the basal cell layer, but also is seen in all neoplastic secretory cells. In carcinoma, the basal cell layer is completely lacking, and labeling of almost all tumor cells is seen. These findings strongly implicate that the VEGF-Flk-1 system may be important for malignant transformation. This is further supported by our findings in carcinomas with low Gleason scores with a decreased marker expression compared with high-grade carcinomas. However, although the value of these observations is limited owing to the small number of tumors, our findings for VEGF are in accordance with those of other authors, 6 who also showed a trend of increasing VEGF expression with dedifferentiation when analyzing 45 prostate carcinomas. Flk-1 staining results correspond only in part to those of other authors. Ferrer et al 12 reported positive Flk-1 staining in only 10 (59%) of 17 tumors. All low-and moderate-grade tumors in their study were positive for Flk-1, whereas none of the high-grade tumors showed anti-Flk-1 immunoreactivity. In our hands, all carcinomas with a Gleason score of 7 to 9 (n = 11) showed more than 75% of the tumor cells stained positive for Flk-1. Staining intensity was strong in 10 cases (91%) and moderate in 1 case (9%), whereas staining intensity was low to moderate in 3 of 4 carcinomas with a Gleason score of 4 to 5. Antigen retrieval by microwave pretreatment as performed in our study may contribute in part to these divergent findings.
Conclusion
Our findings imply that the VEGF-Flk-1 system may be of major importance for tumor development and progression. The simultaneous shift of basal VEGF and Flk-1 expression in benign glands toward a diffuse and more intense labeling in HGPIN and prostatic carcinoma allows us to speculate that tumor growth stimulated by the VEGF-Flk-1 system is promoted not only by stimulation of neoangiogenesis but also by tumor cell autostimulation. Whether these findings may be of clinical importance is unknown. However, therapeutic manipulation of the VEGF-Flk-1 system may become of clinical interest in the treatment of hormone-escaped prostate cancer. Although there is increasing evidence that neoangiogenesis and VEGF production are at least in part androgen dependent, [13] [14] [15] hormonal ablation therapy does not necessarily completely suppress VEGF expression in prostate cancer cells. 9 Reports on elevated serum VEGF levels in patients with hormone-escaped prostate cancer suggest a role in the pathogenesis of advanced disease. 16 Therefore, the VEGF-Flk-1 system may represent a promising new target in the medical treatment of prostate cancer.
